101. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
- Author
-
Hess, Georg, Dreyling, Martin, Oberic, Lucie, Gine, Eva, Zinzani, Pier Luigi, Linton, Kim, Vilmar, Adam, Jerkeman, Mats, Chen, Jenny M. H., Ohler, Anke, Stilgenbauer, Stephan, Thieblemont, Catherine, Lambert, Jonathan, Zilioli, Vittorio Ruggero, Sancho, Juan-Manuel, Jimenez-Ubieto, Ana, Fischer, Luca, Eyre, Toby A., Keeping, Sam, and Park, Julie E.
- Subjects
MANTLE cell lymphoma ,BRUTON tyrosine kinase ,PROTEIN-tyrosine kinase inhibitors ,PROGNOSIS ,OVERALL survival - Abstract
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF